1Roden MM,Zaoutis TE,Buchanan WL. Epidemiology and outcome of zygomycosis:a review of 929 reported cases[J].{H}Clinical Infectious Diseases,2005,(5):634-653.
2Ruping M J,Heinz W J,Kindo A J. Forty-one recent cases of invasive zygomycosis from a global clinical registry[J].{H}Journal of Antimicrobial Chemotherapy,2010,(2):296-302.
3Skiada A,Pagano L,Groll A. Zygomycosis in Europe:analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007[J].{H}Clinical Microbiology and Infection,2011,(12):1859-1867.
4Spellberg B,Walsh TJ,Kontoyiannis DP. Recent advances in the management of mucormycosis:from bench to bedside[J].{H}Clinical Infectious Diseases,2009,(12):1743-1751.
5Zhao Y,Zhang Q,Li L. Primary cutaneous mucormycosis caused by Rhizomucor variabilis in an immunocompetent patient[J].{H}MYCOPATHOLOGIA,2009,(5):243-247.
6Ibrahim AS,Gebermariam T,Fu Y. The iron chelator deferasirox protects mice from mucormycosis through iron starvation[J].{H}Journal of Clinical Investigation,2007,(9):2649-2657.
7Gonzalez CE,Couriel DR,Walsh TJ. Disseminated zygomycosis in a neutropenic patient:successful treatment with amphotericin B lipid complex and granulocyte colony-stimulating factor[J].{H}Clinical Infectious Diseases,1997,(2):192-196.
8Garcia-Diaz JB,Palau L,Pankey GA. Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor[J].{H}Clinical Infectious Diseases,2001,(12):e145-e150.
9Skiada A,Lanternier F,Groll AH. Diagnosis and treatment of mucormycosis in patients with hematological malignancies:guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)[J].{H}HAEMATOLOGICA,2013,(4):492-504.
